NewcelX Strengthens Its Scientific Expertise
NewcelX Ltd. (Nasdaq: NCEL), a clinical-stage biotechnology company, has exciting news to share. The company is dedicated to developing innovative cell-based and small-molecule therapies specifically targeting neurodegenerative and metabolic diseases. Recently, NewcelX welcomed Prof. Jeremy Shefner, MD, PhD, to its Scientific Advisory Board (SAB). This strategic appointment aims to enhance the company’s research and development efforts in the domain of ALS and other related conditions.
Who is Prof. Jeremy Shefner?
Prof. Shefner is renowned in the field of neurology, particularly for his specialization in amyotrophic lateral sclerosis (ALS) as well as neuromuscular disorders. He holds the prestigious position of Professor of Neurology and Chief Medical Officer for Clinical Research at the Barrow Neurological Institute. This institute is recognized globally for its pioneering work in treating neurological diseases and hosts one of the largest multidisciplinary brain and spine programs in the U.S. Additionally, it leads the world in Phase 0 clinical trials aimed at advancing innovative neurotherapeutics.
A Leader in ALS Research
Prof. Shefner's contributions to ALS research are extensive. He co-founded the Northeast ALS Clinical Trials Consortium (NEALS) and has authored over 200 peer-reviewed publications focusing on clinical trial design, ALS biomarkers, and effective outcome measures. His wealth of knowledge and experience is set to benefit NewcelX significantly.
Role on the Scientific Advisory Board
As a member of NewcelX's SAB, Prof. Shefner will play a vital role in shaping the company's strategic initiatives, particularly around the clinical development of AstroRx®, its flagship therapy for ALS. His insights will integrate vital neuromuscular and neurodegenerative disease expertise into NewcelX’s broader platform of cell therapy and neuroscience innovation.
Commitment to Scientific Excellence
The Executive Chairman and CEO of NewcelX, Ronen Twito, expressed his enthusiasm about this appointment. He stated, "We are very pleased to welcome Prof. Shefner to our Scientific Advisory Board. His leadership in ALS research and trial methodology strengthens our ability to bring advanced therapies to patients living with this devastating disease. His appointment underscores our commitment to scientific excellence and rigorous clinical execution." This sentiment reflects the firm’s dedication to innovation in the healthcare space.
Prof. Shefner’s Perspective
When asked about his new role, Prof. Shefner shared, "It is a privilege to join NewcelX's SAB at this pivotal moment. I believe the Company's integrated approach—combining cell therapy and neuroscience—has significant potential to address ALS and other neurodegenerative diseases." His conviction adds an important layer of optimism to the company’s ongoing efforts.
About NewcelX Ltd.
NewcelX Ltd. is on a mission to develop transformative therapies for individuals grappling with neurodegenerative diseases. Its innovative approach merges advanced stem-cell technologies with deep expertise in neuroscience. Notably, the company focuses on delivering scalable, life-altering treatments intended for conditions such as ALS and Type 1 Diabetes. NewcelX is headquartered in Zurich, Switzerland, while also maintaining active research and development operations in Israel, further expanding its innovative capabilities.
Engaging with Science and Innovation
In this era of scientific advancement, NewcelX maintains a strong presence through social media platforms, including LinkedIn, Facebook, and X, ensuring engagement with the community and stakeholders interested in its mission.
Frequently Asked Questions
What is NewcelX Ltd primarily focused on?
NewcelX Ltd specializes in developing cell-based and small-molecule therapies targeting neurodegenerative and metabolic diseases.
Who is Prof. Jeremy Shefner?
Prof. Jeremy Shefner is a prominent neurologist and the Chief Medical Officer at the Barrow Neurological Institute, specializing in ALS and neuromuscular disorders.
What role will Prof. Shefner play at NewcelX?
He will provide strategic guidance regarding the company's programs in ALS and support the integration of expertise in neuromuscular and neurodegenerative diseases.
What is AstroRx®?
AstroRx® is a clinical therapy being developed by NewcelX, focusing on treating ALS and enhancing patient outcomes.
Where is NewcelX Ltd headquartered?
NewcelX is headquartered in Zurich, Switzerland, with research and development operations in Israel.
